HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
Starting soon · Phase 2
Conditions studied: Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
In brief
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB
Key facts
- Study ID
- NCT07575308
- Run by
- Alnylam Pharmaceuticals
- People needed
- 24
- Starts
- 2026-07-31
- Expected to finish
- 2028-11-29
- Last updated by the study team
- 2026-07-14
Who can join
Age: 16 and older, up to 45. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Clinical Trial Site — Miami, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.